Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
Understanding Autism: Insights from Research and Practice
Beyond the Endpoint
26 minutes 2 seconds
2 months ago
Understanding Autism: Insights from Research and Practice
Ushering in the second season of Beyond the Endpoint, Lauren Franz, MBChB, MPH, interim director of the Duke Center for Autism and Brain Development, joins Manesh Patel and Emily O'Brien for an in-depth conversation about autism research, care, and community. Franz explains what autism is as a neurodevelopmental spectrum condition and how our understanding of it has evolved significantly over the last decade. The discussion examines the intricate interplay between genetic and environmental factors that may contribute to the development of autism, and explores current intervention approaches. The hosts and guest also discuss the groundbreaking research at Duke University that employs artificial intelligence to analyze medical records for earlier detection of autism. This approach could help shorten the time between when autism can be diagnosed and when it is typically identified. Throughout the episode, Franz stresses the importance of involving the autism community in research and decision-making processes.
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
